Adults 18 to 75, any sex, with Glabellar Frown Lines. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Investigator's Rating of Glabellar Line Severity at Maximum Frown by Live Assessment.Primary· at Day 30
Subjects included in the analysis had to have a baseline glabellar line (GL) severity rating at maximum frown of moderate (2) or severe (3). The GL severity were measured using a 4-point scale (0: none; 1: mild; 2: moderate; 3: Severe). A responder was defined as having a severity rating of none (0) or mild (1) at the corresponding post-baseline visit. Percentages are based on the number of subjects with an assessment at the relevant visit (Day 30).
Group
Value
95% CI
MT10109 A Unit
18
MT0109 B Unit
18
MT10109 C Unit
22
Botox (Registered Trade Mark)
19
MT10109 A Unit
12
MT0109 B Unit
8
MT10109 C Unit
3
Botox (Registered Trade Mark)
7
Adverse events — posted to ClinicalTrials.gov
Time frame: Until the End-of-Study Visit (Day 120).
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
MT10109 A Unit
Serious: 0/31 (0%)
Deaths: —
MT10109 B Unit
Serious: 0/31 (0%)
Deaths: —
MT10109 C Unit
Serious: 1/27 (4%)
Deaths: —
Botox (Registered Trade Mark)
Serious: 1/32 (3%)
Deaths: —
Serious adverse events (2 terms)
Reaction
System
MT10109 A Unit
MT10109 B Unit
MT10109 C Unit
Botox (Registered Trade Ma…
Cholelithiasis
Hepatobiliary disorders
—
—
—
—
Breast Cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
The purpose of this study is to find an optimal dose to determine the safety and tolerability of a single dose of MT10109(clostridium botulinum type A) administered by intramuscular injection in subjects with glabellar lines compared with the standard dose of BOTOX®
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medy-Tox
Last refreshed: 22 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01485601.